Experimental study kg New Zealand white) were treated with sodium warfarin (daily subcutaneous injection), the dosage being adjusted until the BCR was raised to a steady level (at dose 0 40 0O04 mg), after which they were also treated with amiodarone chloride solution (Reckitt and Colman) 35 1.-t 3 4 6 7 8 9 10 nD 1 2 3 4 5 6 7 89 10 ln 12 Days
Effect of treatment with amiodarone on British corrected ratio of prothrombin times (BCR).
given in daily subcutaneous injections for four days. Venous blood samples (ear vein) were collected in HEPES-buffered trisodium citrate solution for measurement of prothrombin time,' using both human and rabbit brain thromboplastin (Thromboplastin CAHS (UK) Ltd) and derivation of BCR.
Results are given as mean I SE and compared by paired Student's t test. The addition of amiodarone resulted in a significant and striking increase in BCR from a stable level of 2 6±0 38 (n~5) before amiodarone, to 5 4±1 4 on day 1, 13 3±440 on day 2, and 6-2±0 59 (n=3, two rabbits having died from gastrointestinal haemorrhage) on day 3, using human thromboplastin; or from 1-9±0 21 to 4 0±111, 9 113-9, and 3 6140 45 respectively, using rabbit thromboplastin.
Comment
Although not yet released for general use in Britain, amiodarone is widely used abroad and under hospital supervision in Britain. It has valuable antiarrhythmic properties2 3 associated with prolongation of action potential duration as well as slowing of action potential upstroke and thus conduction velocity.4 The need for special care in using amiodarone in combination with anticoagulant drugs has not been recognised. This case report and experimental study clearly indicate the need for great caution in this respect. The Committee for Safety in Medicine has in fact received some reports suggesting such an interaction (personal communication). Amiodarone is highly (>90%') protein bound in the blood.5 A possible explanation of the interaction is therefore that it displaces warfarin from protein-binding sites. Alternatively it could influence warfarin metabolism. This has important therapeutic implications for its clinical use in combination with many drugs.
Emergency treatment of high blood pressure with oral atenolol Reduction of blood pressure within two hours with parenteral treatment is necessary in only a few well-defined clinical conditions, such as hypertensive encephalopathy and eclampsia. If pressure is reduced too quickly ischaemia of the heart, brain, or kidneys or blindness may ensue.' 2 3With the exception of these dire emergencies, oral antihypertensive treatment may suffice, but even this may carry some hazard.' We have used a single oral dose of the cardioselective beta-blocker atenolol in very severe hypertension in an attempt to control blood pressure smoothly and avoid rapid falls.
Patients, methods, and results
Patients with blood pressures exceeding 200/130 mg Hg or with malignant hypertension were treated with 100 mg atenolol by mouth in a single dose. Patients in whom beta-blockers were contraindicated or in whom we suspected a phaeochromocytoma were excluded. Blood pressures were measured by the nursing staff, using standard sphygmomanometers and the fifth phase as diastolic pressure in the resting supine position for at least two hours before and for 12 hours after drug administration. "Pretreatment" blood pressure was taken as that reached when the pressure had stabilised after at least two hours of bed rest.
We studied eight men and two women. All were Caucasians, and their mean age was 46 (range 15-62 years). Nine had malignant hypertension, and only one was receiving treatment. There was a mean fall in pressure of 56 mm Hg systolic and 40 mm Hg diastolic over 12 hours. No side effects were encountered, and blood-pressure control was achieved smoothly without precipitous drops (table). Nine subjects had normal excretion urograms, serum electrolyte concentrations, and 24-hour urinary output of metanephrines. The remaining patient had evidence of renal artery stenosis on excretion urography.
Reduction of blood pressure in 10 patients after oral atenolol. 
Comment
Atenolol is rapidly absorbed after oral administration4 and is therefore suitable for patients who require rapid reduction of blood pressure. Other studies have shown that labetalol given by mouth is adequate for severe and accelerated hypertension,5 and we have found that a beta-blocker alone appears to have an adequate hypotensive effect in malignant hypertension. The prolonged antihypertensive effect of atenolol provides a further advantage in that subsequent doses need not be given for 12-18 hours, though all the present patients subsequently required further drugs to control their blood pressure. Blood pressures after 12 hours were not normal, but a gradual reduction is more important than to achieve this. We emphasise that beta-blockade alone can be harmful where a phaeochromocytoma is suspected. Although hypertension and renal disease are common in polyarteritis nodosa, the mechanism of the hypertension is not well understood. Three cases have been described in which hypersecretion of renin appeared to be an important mechanism.1 2 We report a case that has striking similarities with the three others and suggests the possibility of a common underlying pattern.
Case report
A previously healthy 46-year-old white man developed arthralgia, rash, anorexia, weight loss, mononeuritis multiplex, and hypertension. Investigations showed that he was positive for hepatitis B surface antigen and had hyponatraemia (serum sodium 128 mmol(mEq)/l), hypokalaemia (serum potassium 2-7 mmol(mEq)/l), and a creatinine clearance of 70 ml/min.
A liver biopsy specimen showed changes of persistent hepatitis.
Plasma renin activity was 20 mmol/l/h(26 ng/ml/h), urine sodium excretion 320 mmol/24 h, and urine aldosterone excretion 0-2 umol(71 pg)/24 h. These findings were characteristic of polyarteritis nodosa, and he was treated with cyclophosphamide, propranolol, prazosin, and triamterenehydrochlorthiazide (Dyazide), on which regimen the plasma renin activity fell to 5-8 mmol/l/h(7-5 ng/ml/h) and blood pressure to 124/78 mm Hg.
Comment
The clinical history of this patient strongly suggested renovascular disease as the cause of the sudden onset of severe hypertension, hyponatraemia, and hypokalaemia. Peripheral plasma renin activity was extremely high, at a value normally seen only in patients with malignant hypertension or tight unilateral renal artery stenosis. That the hyperreninaemia was itself responsible for the raised pressure was shown by the dramatic effect of a small dose of captopril in lowering blood pressure.
The suggestion that the hypertension of polyarteritis nodosa might be due to renal ischaemia occurring as a result of vasculitis of the renal arterioles was first made by Dawson et al in 1948,3 but evidence for this mechanism has so far been lacking. In only one reported case2 have renin measurements of the kind reported here been made, and in one other case the blood pressure was responsive to captopril.2 A third case, in which the hypertension was shown to be angiotensin dependent by a hypotensive response to saralasin, was reported by Stockigt et al. 1 The similarity of these four patients is striking. All had typical features of polyarteritis nodosa, with hypertension of recent onset, and were positive for hepatitis B surface antigen, which is normally found in about 30% of patients with polyarteritis.4 The renal findings are particularly interesting. Renal vein renin measurements were performed in three cases, and all showed bilateral hypersecretion of renin, high aldosterone values, and hypokalaemia. Renal arteriography showed bilateral intrarenal aneurysms characteristic of polyarteritis nodosa, but creatinine clearance was surprisingly well preserved, ranging between 70 and 120 ml/min in the four patients. The renin-angiotensin system was responsible for the hypertension in three of the four cases: in one this was shown by testing with saralasin, and in two with captopril. Since the onset of hypertension has been reported in 20% of patients with polyarteritis nodosa,5 measurements of renin activity are likely to be particularly helpful in evaluating such patients. This has small and almost round leaves, yet a little pointed and without dent or cut, of a dusky mealy colour, growing on the slender stalks and branches that spread on the ground, with small flowers set with the leaves, and small seeds succeeding like the rest, perishing yearly, and rising again with its own sowing. It smells like rotten fish, or something worse.
It grows usually upon dunghills. They flower in June and July, and their seed is ripe quickly after.
Stinking Arrach is used as a remedy to women pained, and almost strangled with the mother, by smelling to it; but inwardly taken there is no better remedy under the moon for that disease. I would be large in commendation of this herb, were I but eloquent. It is an herb under the dominion of Venus, and under the sign Scorpio; it is common almost upon every dunghill. The works of God are freely given to man, his medicines are common and cheap, and easily to be found. I commend it for an universal medicine for the womb, and such a medicine as will easily, safely, and speedily cure any disease thereof, as the fits of the mother, dislocation, or falling out thereof; cools the womb being over-heated. And let me tell you this, and I will tell you the truth, heat of the womb is one of the greatest causes of hard labour in child-birth. It makes barren women fruitful. It cleanseth the womb if it be foul, and strengthens it exceedingly; it provokes the terms if they be stopped, and stops them if they flow immoderately; you can desire no good to your womb, but this herb will affect it; therefore if you love children, if you love health, if you love ease, keep a syrup always by you, made of the juice of this herb, and sugar (or honey, if it be to cleanse the womb), and let such as be rich keep it for their poor neighbours; and bestow it as freely as I bestow my studies upon them, or else let them look to answer it another day, when the Lord shall come to make inquisition for blood. (Nicholas Culpeper (1616 -54) The Complete Herbal, 1850 
